{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-23-000378","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2023-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.965883+00:00","generated_at":"2026-06-13T16:39:00.687502+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"KORU Medical appoints Andrew LaFrence as CFO, effective July 10, 2023","bullets":["Andrew LaFrence brings 39 years of finance/accounting experience; previously CFO at Vyant Bio and Surmodics, 26 years at KPMG.","Base salary of $350k per year; eligible for annual cash bonus up to 50% of base salary.","Inducement option to purchase 300,000 shares of common stock, vesting 25% annually over 4 years.","Tom Adams, interim CFO, will continue as VP of Financial Planning and Analysis.","LaFrence will support the Vision 2026 growth strategy and scaling of the business."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-23-000378","json":"https://secwatch.observer/filing/0001161697-23-000378.json","markdown":"https://secwatch.observer/filing/0001161697-23-000378.md","text":"https://secwatch.observer/filing/0001161697-23-000378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000378/0001161697-23-000378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000378/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T16:39:00.687502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33c88f9043","claim":"Thomas Adams changed role as Vice President of Financial Planning and Analysis at KORU Medical Systems, Inc..","evidence_excerpt":"Thomas Adams, Interim Chief Financial Officer, will continue as the Company’s Vice President of Financial Planning and Analysis upon the appointment of Mr. LaFrence.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000378/0001161697-23-000378-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"role change"},{"label":"Role","value":"Vice President of Financial Planning and Analysis"}],"fact_type":"executive_change"},{"claim_id":"6b95fcb1c9","claim":"Andrew D. C. LaFrence was appointed as Chief Financial Officer at KORU Medical Systems, Inc..","evidence_excerpt":"Andrew D. C. LaFrence has been employed by KORU Medical Systems, Inc. (the “Company”) to serve as its Chief Financial Officer commencing July 10, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000378/0001161697-23-000378-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}